April.16.2016
Crelux GmbH has been sold by its founding shareholders to Chinese pharma platform WuXi AppTec.
The parties agreed to keep the transaction volume confidential.
Crelux is a provider of high-quality solutions for early stage drug development. As a global leader in structure-based drug discovery, Crelux has been providing the drug discovery industry with highly individualized and efficient solutions to inform and accelerate their programmes for more than a decade. WuXi AppTec is a leading pharmaceutical, biotechnology, and medical device R&D platform company with global operations. With the acquisition of Crelux, WuXi AppTec sets a solid foundation to expand its integrated drug discovery services within Europe.
Orrick already acted several times for the founders of Crelux under the lead of Munich Partner Dr. Jörg Ritter. In this transaction the new Partner Dr. Fabian von Samson-Himmelstjerna took the lead. He joined Orrick Munich in early 2016 from Ashurst Frankfurt.
Advisors of the Crelux shareholders:
Orrick, Herrington & Sutcliffe (Munich): Dr. Fabian von Samson-Himmelstjerna (Corporate/M&A, lead), Dr. Jörg Ritter (Corporate/M&A), Dr. André Zimmermann (Employment, Düsseldorf), Dr. Stefan Schultes-Schnitzlein (Tax, Düsseldorf); Associates: Dr. Nicolas Mähner (Corporate/M&A), Julia Schmitz (International Arbitration, Düsseldorf)